Biocon Biologics on Monday announced a transformational deal to acquire partner Viatris’ global biosimilars business for up to USD 3.335 billion in cash and stock. The acquisition of the business, which is estimated to generate revenues of USD 1 billion next year, will create a unique, fully integrated global biosimilars enterprise. Kiran Mazumdar-Shaw, Executive Chairperson, … Continue reading A game-changing, transformational deal that is an inflection point in Biocon Biologic’s journey of making global impact: Kiran Mazumdar-Shaw
In a recent talk with Mike Milken from the Milken Institute, Kiran Mazumdar-Shaw shared her views on Compassionate Capitalism while talking about "Responding to Covid-19". “I'm very committed to compassionate capitalism, which is what I like to call my business....My products are there to help patients who need it anywhere in the world. And therefore, … Continue reading #Podcast: Compassionate Capitalism, with Kiran Mazumdar-Shaw by Milken Institute
Biocon CMD Kiran Mazumdar-Shaw tells ET Now in an interview that the Company remains extremely confident of delivering very strong numbers in its Biologics business this fiscal, with a more robust performance in the second half of the year on the back of the commercialization of biosimilar Trastuzumab in the U.S. market. She also talks … Continue reading Podcast: Kiran Mazumdar – Shaw speaks to ET Now on strong performance of biosimilars business and Biocon Biologics’ growth prospects.